This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Biotech Stock Mailbag: Dendreon's Aftermath

BOSTON ( TheStreet) -- I typically write the bulk of the Biotech Stock Mailbag on Thursday, so as I type, the markets are in meltdown and a conflagration has consumed the biotech sector. Memo to Dendreon (DNDN) CEO Mitch Gold: Nice timing, my friend. Real nice.

It's unfair to lay all the blame for the "end of biotech as we know it" at Dendreon's doorstep, but I don't believe we'd be experiencing such a sharp, swift and broad selloff had Dendreon pulled off a normal quarter. The Provenge miscue spooked a lot of biotech investors who were already on edge.

In my Dendreon column Thursday, I wrote, "The ill effects of the Dendreon debacle will unfortunately spread beyond the company's stock price and its shareholders to infect the entire biotech sector."

To which Brandon M. comments, "Disasters of this magnitude raise the question of whether the biotech sector is even investable for individuals/home gamers because even if you pick the right company, right drug and get the timing correct through the myriad of approvals with the FDA etc., the follow-on execution risks are just as daunting…

"How many times does lightning have to strike in a biotech stock for people to make enough money to offset all the misses? Well, for those who play on the wrong side, the ratio just went the wrong way ... again. Doesn't this raise a fundamental question as to whether the commercial development model needs tweaking as far as capital markets are concerned? If Provenge is a miracle drug but withers on the vine because it costs $93,000, where are we?"

I've reached a point at which it feels safer not to recommend, write about or even whisper the name of a biotech company about to embark on a drug launch. Dendreon may turn out to be the biggest biotech drug-launch flop in history, rivaling the Medimmune Flumist disaster (thanks for reminding me of that one, Lazard's Joel Sendek); or if you want to extend the category, there's the Pfizer (PFE)- Nektar Therapeutics (NKTR) Exubera fiasco.

Biotech investing is hard, but biotech investing after a drug approval and/or right before a drug launch has become impossible, unless you're short, which seems as risk-free as investing in T-bills, with much higher returns.

I thought Amag Pharmaceuticals (AMAG - Get Report) would do well launching Feraheme. Wrong! I was bullish on Allos Therapeutics (ALTH) going into the Folotyn launch. Wrong! More recently, I thought Optimer Pharmaceuticals (OPTR) would hold up well as preparations for the Dificid launch gets under way. Wrong again!

I finally learned my lesson and got one right with Seattle Genetics (SGEN - Get Report), warning folks that the stock was expensive ahead of the likely approval of Adcetris later this month.

Brandon raises a good question. The relationship between the capital markets, i.e., investors and companies entering the commercial phase of their lifespan does seem broken. Why? I don't know for sure, but it may relate to the shortsighted or short-term nature of biotech investing these days. Long-term investing seems extinct, with investors morphing into traders only interested in the next catalyst -- clinical trial results, FDA advisory panels, drug approval decisions.

1 of 6

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
PATH $0.00 0.00%
AMAG $68.52 2.74%
DNDN $0.06 -6.02%
SPPI $6.22 -0.32%
SGEN $43.16 1.55%

Markets

DOW 18,126.12 -36.87 -0.20%
S&P 500 2,120.79 -2.69 -0.13%
NASDAQ 5,097.9760 -8.6170 -0.17%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs